付琴，华中科技大学同济医学院基础医学院药理学系教授，博士生导师。德国柏林Max-Delbrueck分子医学中心访问学者；美国伊利诺伊大学香槟分校和加州大学戴维斯分校博士后。现任中国药理学会心血管药理学专业委员会常务委员，表观遗传药理专业委员会委员，湖北省药理学会副理事长。担任Diabetes，British Journal of Pharmacology，Pharmacological Research，FASEB Journal等期刊特约审稿人。主持多项国家自然科学基金面上项目以及海外合作项目；研究成果发表在Circulation、Diabetes、JMCC、BJP、JBC等期刊，并获得湖北省科技进步一等奖（2019）。

主要研究方向：

1. 心血管疾病和代谢综合征的发病机制和药物干预靶点

2. 肾上腺素受体/磷酸二酯酶信号通路调控心脏和肝脏疾病的作用机制

联系方式：fuqin@tjmu.edu.cn

承担课题：

1.国家自然科学基金，β2肾上腺素受体调控CD36介导的心肌细胞和心脏成纤维细胞代谢重塑在心梗后心衰中的双向作用及机制研究

2.国家自然科学基金，PDE4调控的心脏成纤维细胞miR-1应答高胰岛素血症在糖尿病心肌纤维化中的作用机制及干预研究，

3.国家自然科学基金海外及港澳学者合作研究基金延续项目，β2肾上腺素受体依赖性的胰岛素促心肌GLUT4转运对β受体阻滞剂抗糖尿病心力衰竭疗效的影响

4.国家自然科学基金，β2肾上腺素受体依赖性的胰岛素诱导的PDE4在糖尿病心功能不全中的作用

5.国家自然科学基金海外及港澳学者合作研究基金，神经激素对β肾上腺素受体阻断剂抗心力衰竭疗效的影响，

6.国家自然科学基金，ERK1/2-CX43信号通路在β2肾上腺素受体激动剂抗心肌缺血再灌注损伤中的作用

发表学术论文（#Co-first author , *Co-corresponding author)：

1. Fu Q,Wang Y, Yan C, Xiang YK. Phosphodiesterases in heart and vessels- From Physiology to Diseases. Physiol Rev.2024 Apr 1;104(2):765-834.

2. Fu J^#, Li L^#, Chen L, Su C, Feng X, Huang K, Zhang L*, Yang X*,Fu Q*. PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2. J Mol Cell Cardiol. 2022 Nov; 172:63-77.

3. Xu R^#, Fu J^#, Hu Y, Yang X, Tao X, Chen L, Huang K,Fu Q. Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.Diabetes. 2022 2022 Aug 1;71(8):1660-1678.

4. Ren H, Chen Y, Ao Z, Cheng Q, Yang X, Tao H, Zhao L, Shen A, Li P*,Fu Q*.PDE4D binds and interacts with YAP to cooperatively promote HCC progression.Cancer Lett. 2022 Aug 10;541:215749

5. Xu R, Feng S, Chen Y, Ao Z, Su C, Feng X,Fu Q*, Yang X*.Long-Acting β2 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis.Front. Pharmacol. 2022 Jun 20:13:865715

6. Tao X, Chen C, Chen Y, Zhang L, Hu J, Yu H, Liang M,Fu Q*, Huang K*. β2-adrenergic receptor promotes liver regeneration partially through crosstalk with c-met.Cell Death Dis. 2022 Jun 27;13(6):571

7. Tao X, He H, Peng J, Xu R, Fu J, Hu Y, Li L, Yang X, Feng X, Zhang C, Zhang L, Yu X, Shen A*, Huang K*,Fu Q*. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.Pharmacol Res. 2022 Jan;175:106004.

8. Xu R^#, Gopireddy RR^#, Wu Y^#, Wu L, Tao X, Shao J, Wang W, Li L, Jovanovic A, Xu B, Kenyon NJ, Lu Q, Xiang YK*,Fu Q*. Hyperinsulinemia promotes heterologous desensitization of β2 adrenergic receptor in airway smooth muscle in obesity.FASEB J. 2020 Mar;34(3):3996-4008.

9. Fu Q^*, Wang Q^*, Xiang YK^*Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.Trends Endocrinol Metab. 2017 Jun;28(6):416-427 .

10. Wang Q^#, Liu Y^#,Fu Q^#, Xu B, Zhang Y, Kim S, Tan R, Barbagallo F, West T, Anderson E, Wei W, Abel ED, Xiang YK. Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.Circulation. 2017 Jan 3;135(1):73-88.

11. Fu Q^#*,Kim S^#, Soto D, De Arcangelis V, Dipilato L, Liu S, Xu B, Zhang J, Shi Q, Xiang YK*. A long-lasting β1 adrenergic receptor stimulation of cAMP/PKA signals in cardiac myocytes. J Biol Chem.2014 May 23;289(21):14771-81

12. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y, Zhang Y, Riehle C, Zhu Y, Rawlings T, Shi Q, Clark RB, Chen X, Abel ED, Xiang YK. Insulin inhibits cardiac contractility by inducing a Gi-biased β2 adrenergic signaling in hearts.Diabetes.2014 Aug;63(8):2676-89

13. Fu Q^*, Hu Y, Wang Q, Liu Y, Li N, Xu B, Kim S, Chiamvimonvat N, Xiang YK^*. High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β(2) -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts.J Physiol. 2017 Mar 15;595(6):1973-1986.